Quick Answer
BRAINSTORM CELL THERAPEUTICS INC. reported Cash and Equivalents of $29.0 thousand for fiscal year 2025.
BRAINSTORM CELL THERAPEUTICS INC. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $29.0K | -84.5% |
| 2024 | $187.0K | -85.6% |
| 2023 | $1.30M | +68.4% |
| 2022 | $772.0K | -95.9% |
| 2021 | $18.86M | -50.2% |
| 2020 | $37.83M | +6957.6% |
| 2019 | $536.0K | -43.1% |
| 2018 | $942.0K | -62.1% |
| 2017 | $2.48M | +353.9% |
| 2016 | $547.0K | +27.8% |
| 2015 | $428.0K | -89.9% |
| 2014 | $4.25M | +21.4% |
| 2013 | $3.50M | +166.0% |
| 2012 | $1.32M | +56.2% |
| 2012 | $843.0K | -56.2% |
| 2011 | $1.92M | -33.7% |
| 2011 | $2.90M | -20.9% |
| 2011 | $3.66M | +3839.8% |
| 2010 | $93.0K | -87.6% |
| 2010 | $749.0K | +74800.0% |
| 2009 | $1.0K | — |
| 2000 | $0.00 | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $5.0K | -97.0% | -99.4% |
| June 30, 2025 | $824.0K | -76.2% | -49.9% |
| March 31, 2025 | $1.64M | +111.0% | +779.1% |
| December 31, 2024 | $187.0K | -85.6% | +11.3% |
| September 30, 2024 | $168.0K | -86.3% | -95.2% |
| June 30, 2024 | $3.47M | +535.3% | +345.3% |
| March 31, 2024 | $779.0K | -61.5% | -40.1% |
| December 31, 2023 | $1.30M | +68.4% | +6.4% |
- BRAINSTORM CELL THERAPEUTICS INC. showed a decrease of -84.5% in Cash and Equivalents compared to the prior fiscal year.
- The most recent figure is from BRAINSTORM CELL THERAPEUTICS INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: